Most Recent
Construction PRO
The High Court of Australia will hear the appeal of a failed class action over the planned demolition of inner-city public housing towers in Melbourne, which will involve consideration of the right to remain in settled social communities.
Construction PRO
A judge has permanently stayed a suit against developer Stennson over a Caulfield North residential development after finding the developer would suffer prejudice because the builder on the project was not a party in the case.
Construction PRO
A landlord has won its bid to have lost rent and outgoings assessed as part of damages it is owed after a judge found baked goods producer Allied Pinnacle was required to repaint the outside when its commercial lease at a Western Sydney property ended.
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.
Supermarket giant Woolworths has been hit with a lawsuit by a former senior executive who claims she was forced to work up to 90 hours per week and was subjected to a "boys club" culture.
Construction PRO
A judge has tossed an environmental group's bid for judicial review of a minister's approval of plans to build water regulating structures at the Nyah Floodplain in Victoria, saying the approval was contingent on plans to offset effects on the Regent parrot.
Two class actions against the state of Queensland over the removal of Indigenous children from their families are set to be discontinued after losing litigation funding.
Construction PRO
The Albanese government is set to spend $2 billion over the next four years to fund critical infrastructure to bolster housing supply.
Boral's former CEO Zlatko Tordorcevski and ex-CFO Tino La Spina have been granted discovery as they mull possible claims against their former employer for curbing their long-term incentive entitlements when they left in 2022.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.